At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 242 enrolled
Drug / intervention
Lebrikizumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Open-Label, Single-Dose Bioequivalence Study of Injections of Lebrikizumab Using a 2-mL Pre-Filled Syringe With Needle Safety Device and an Investigational 2-mL Autoinjector in Healthy Participants
In Brief
A Phase 1 clinical trial evaluating Lebrikizumab for Healthy. Completed, enrolled 242 participants across 4 sites.
Detailed Summary
The main purpose of this study is to look at the amount of the study drug, lebrikizumab, that gets into the blood stream and how long it takes the body to get rid of lebrikizumab (LY3650150) when given using either a pre-filled autoinjector (AI) or a pre-filled syringe with needle safety device (PFS-NSD). The safety and tolerability of lebrikizumab will also be evaluated. The study will last up to 102 days.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
20222023202420252026
First PostedApr 2021
Enrollment StartJun 2021
Primary CompletionFeb 2022
TodayJul 2026
First PostedApr 12, 2021
Enrollment StartJun 2, 2021
Primary CompletionFeb 11, 2022
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 5.2 years ago
Interventions
Lebrikizumabdrug
Administered SC.